RCT evaluates urolithin A and fisetin on sleep quality and aging biomarkers in middle-aged and older adults
This randomized controlled trial compared four groups—placebo, 500 mg urolithin A, 500 mg fisetin, and a 300 mg urolithin A + 200 mg fisetin combination—over 12 weeks in middle-aged and older adults. Participants took daily capsules and underwent assessments at baseline, week 4, and week 12, including sleep quality measures (PSQI, actigraphy, polysomnography), aging biomarkers (DNA methylation, inflammatory cytokines), and gut microbiome analysis. The abstract describes the study design and planned assessments but does not report any results or findings.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 10, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 3 months
- Population
- Middle-aged and older adults
- Primary outcome
- Sleep quality improvement (measured by PSQI scale, actigraphy, and polysomnography)
- Effect size
- —
- Significance
- Not reported
- Journal
- Huazhong University of Science and Technology
- Published
- Aug 10, 2026
Sources
Primary source
- Huazhong University of Science and Technology ↗Clinical trial
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.